Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

Abstract Management of breast cancer in limited-resource settings is hindered by a lack of low-cost, logistically sustainable approaches toward molecular and cellular diagnostic pathology services that are needed to guide therapy. To address these limitations, we have developed a multimodal cellphon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel Y. Joh, Jacob T. Heggestad, Shengwei Zhang, Grace R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, Amy B. Cheng, Faris Albarghouthi, Jason Liu, Sachi Oshima, Angus M. Hucknall, Terry Hyslop, Allison H. S. Hall, Kris C. Wood, E. Shelley Hwang, Kyle C. Strickland, Qingshan Wei, Ashutosh Chilkoti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/dbe9959994e64aa882ef7c71873c21a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbe9959994e64aa882ef7c71873c21a5
record_format	dspace
spelling	oai:doaj.org-article:dbe9959994e64aa882ef7c71873c21a52021-12-02T16:32:09ZCellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates10.1038/s41523-021-00290-02374-4677https://doaj.org/article/dbe9959994e64aa882ef7c71873c21a52021-07-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00290-0https://doaj.org/toc/2374-4677Abstract Management of breast cancer in limited-resource settings is hindered by a lack of low-cost, logistically sustainable approaches toward molecular and cellular diagnostic pathology services that are needed to guide therapy. To address these limitations, we have developed a multimodal cellphone-based platform—the EpiView-D4—that can evaluate both cellular morphology and molecular expression of clinically relevant biomarkers directly from fine-needle aspiration (FNA) of breast tissue specimens within 1 h. The EpiView-D4 is comprised of two components: (1) an immunodiagnostic chip built upon a “non-fouling” polymer brush-coating (the “D4”) which quantifies expression of protein biomarkers directly from crude cell lysates, and (2) a custom cellphone-based optical microscope (“EpiView”) designed for imaging cytology preparations and D4 assay readout. As a proof-of-concept, we used the EpiView-D4 for assessment of human epidermal growth factor receptor-2 (HER2) expression and validated the performance using cancer cell lines, animal models, and human tissue specimens. We found that FNA cytology specimens (prepared in less than 5 min with rapid staining kits) imaged by the EpiView-D4 were adequate for assessment of lesional cellularity and tumor content. We also found our device could reliably distinguish between HER2 expression levels across multiple different cell lines and animal xenografts. In a pilot study with human tissue (n = 19), we were able to accurately categorize HER2-negative and HER2-positve tumors from FNA specimens. Taken together, the EpiView-D4 offers a promising alternative to invasive—and often unavailable—pathology services and may enable the democratization of effective breast cancer management in limited-resource settings.Daniel Y. JohJacob T. HeggestadShengwei ZhangGrace R. AndersonJayanta BhattacharyyaSuzanne E. WardellSimone A. WallAmy B. ChengFaris AlbarghouthiJason LiuSachi OshimaAngus M. HucknallTerry HyslopAllison H. S. HallKris C. WoodE. Shelley HwangKyle C. StricklandQingshan WeiAshutosh ChilkotiNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Daniel Y. Joh Jacob T. Heggestad Shengwei Zhang Grace R. Anderson Jayanta Bhattacharyya Suzanne E. Wardell Simone A. Wall Amy B. Cheng Faris Albarghouthi Jason Liu Sachi Oshima Angus M. Hucknall Terry Hyslop Allison H. S. Hall Kris C. Wood E. Shelley Hwang Kyle C. Strickland Qingshan Wei Ashutosh Chilkoti Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
description	Abstract Management of breast cancer in limited-resource settings is hindered by a lack of low-cost, logistically sustainable approaches toward molecular and cellular diagnostic pathology services that are needed to guide therapy. To address these limitations, we have developed a multimodal cellphone-based platform—the EpiView-D4—that can evaluate both cellular morphology and molecular expression of clinically relevant biomarkers directly from fine-needle aspiration (FNA) of breast tissue specimens within 1 h. The EpiView-D4 is comprised of two components: (1) an immunodiagnostic chip built upon a “non-fouling” polymer brush-coating (the “D4”) which quantifies expression of protein biomarkers directly from crude cell lysates, and (2) a custom cellphone-based optical microscope (“EpiView”) designed for imaging cytology preparations and D4 assay readout. As a proof-of-concept, we used the EpiView-D4 for assessment of human epidermal growth factor receptor-2 (HER2) expression and validated the performance using cancer cell lines, animal models, and human tissue specimens. We found that FNA cytology specimens (prepared in less than 5 min with rapid staining kits) imaged by the EpiView-D4 were adequate for assessment of lesional cellularity and tumor content. We also found our device could reliably distinguish between HER2 expression levels across multiple different cell lines and animal xenografts. In a pilot study with human tissue (n = 19), we were able to accurately categorize HER2-negative and HER2-positve tumors from FNA specimens. Taken together, the EpiView-D4 offers a promising alternative to invasive—and often unavailable—pathology services and may enable the democratization of effective breast cancer management in limited-resource settings.
format	article
author	Daniel Y. Joh Jacob T. Heggestad Shengwei Zhang Grace R. Anderson Jayanta Bhattacharyya Suzanne E. Wardell Simone A. Wall Amy B. Cheng Faris Albarghouthi Jason Liu Sachi Oshima Angus M. Hucknall Terry Hyslop Allison H. S. Hall Kris C. Wood E. Shelley Hwang Kyle C. Strickland Qingshan Wei Ashutosh Chilkoti
author_facet	Daniel Y. Joh Jacob T. Heggestad Shengwei Zhang Grace R. Anderson Jayanta Bhattacharyya Suzanne E. Wardell Simone A. Wall Amy B. Cheng Faris Albarghouthi Jason Liu Sachi Oshima Angus M. Hucknall Terry Hyslop Allison H. S. Hall Kris C. Wood E. Shelley Hwang Kyle C. Strickland Qingshan Wei Ashutosh Chilkoti
author_sort	Daniel Y. Joh
title	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
title_short	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
title_full	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
title_fullStr	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
title_full_unstemmed	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
title_sort	cellphone enabled point-of-care assessment of breast tumor cytology and molecular her2 expression from fine-needle aspirates
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/dbe9959994e64aa882ef7c71873c21a5
work_keys_str_mv	AT danielyjoh cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT jacobtheggestad cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT shengweizhang cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT graceranderson cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT jayantabhattacharyya cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT suzanneewardell cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT simoneawall cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT amybcheng cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT farisalbarghouthi cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT jasonliu cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT sachioshima cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT angusmhucknall cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT terryhyslop cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT allisonhshall cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT kriscwood cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT eshelleyhwang cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT kylecstrickland cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT qingshanwei cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates AT ashutoshchilkoti cellphoneenabledpointofcareassessmentofbreasttumorcytologyandmolecularher2expressionfromfineneedleaspirates
_version_	1718383840634863616

Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

Ejemplares similares